TESARO is an oncology-focused biopharmaceutical company.
TESARO is dedicated to improving the lives of cancer patients by developing and providing safer and more effective therapeutics and supportive care products.
Contact
TESARO Bio GmbH.
Poststrasse 6
6300 ZUG
Switzerland
| www.tesarobio.com
|
The first company to bring a treatment for metabolic dysfunction-associated steatohepatitis (MASH) to market, Madrigal Pharmaceuticals is redefining how the world tackles fatty liver disease. From its new European base…
As global trade tensions escalate, Switzerland’s export-driven pharmaceutical industry finds itself at a challenging moment. With the United States imposing tariffs of up to 39 percent on Swiss goods and…
Marion Allerstorfer, General Manager of Abbott’s diabetes care business in Switzerland and Austria, shares insights from her two-decade career at the company, highlighting Abbott’s strong people-first culture and its ability…
With over seven decades of innovation behind it, Lupin has evolved from an Indian pioneer in anti-tuberculosis therapies into a global pharmaceutical leader shaping the future of complex generics, speciality…
Clinigen is in the midst of a major transformation, repositioning itself as a pure services partner focused on bridging patient access to critical medicines worldwide. Its recent acquisition of SSI…
Affordability is not necessarily the main barrier to better rare disease therapy access in Europe. Across the continent, orphan availability correlates poorly with GDP per capita, but strongly with health…
SpiroChem has evolved from a niche ETH Zurich spin-out into a global discovery partner recognised for tackling some of the most complex challenges in modern drug design. Over more than…
Giancarlo Benelli, SVP, Head of Europe at BeOne Medicines (BeOne), draws on nearly three decades of pharmaceutical leadership to drive the company’s rapid growth in oncology and haematology in Europe,…
Marc Gitzinger, CEO and Founder of BioVersys, launched the company from his doctoral research at ETH Zurich on antibiotic resistance. Bioversys began with a tuberculosis programme; today, it owns two…
Chantal Friebertshäuser, SVP Europe & Middle East, is spearheading Moderna’s ambitious expansion beyond COVID-19 vaccines, leveraging mRNA technology to target cancers and latent viruses across diverse markets. She champions a…
Neil Archer, Executive Vice President International at Madrigal, discusses the company’s pioneering role in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis), a progressive liver disease with no prior approved therapies. He shares…
QIAGEN’s Sample Technologies portfolio sits at the core of the company’s mission to deliver the highest-quality products to enable valuable molecular insights to more than 500,000 customers across life sciences…
See our Cookie Privacy Policy Here
